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Abstract
Objective
Our aim was to investigate whether trends in quality of diabetes care differ between sexes
in the Netherlands from 1998 till 2013.
Research Design and Methods
In this prospective observational cohort study quality of care was measured using process
and outcome measures in patients with type 2 diabetes in primary care. Trend and absolute
differences between sexes were investigated for patients <75 years. Subgroup analyses
were performed in patients75 years. 10-year mortality risk was assessed with the Globor-
isk risk equation in patients without cardiovascular diseases <75 years.
Results
The number of patients increased from 2,644 in 1998 to 62,230 in 2013. In 1998, 51% of the
men and 60% of the women <75 years had an HbA1c >53 mmol/mol; this decreased to
approximately 29% in both sexes in 2013. Patients having a systolic blood pressure >140
mmHg decreased from 70% to 42%, and from 80% to 40% in men and women <75 years,
respectively. In patients75 years it decreased from 72% to 50% in men and 85% to 56%
in women. Obesity increased in both sexes, whereas smoking in men and women declined
in patients <75 years (men: 34% to 22%; women: 22% to 18%). The number of patients with
a mortality risk >20% over 10 years decreased from 15% to 3% in men and from 18% to 3%
in women.
Conclusions
Quality of diabetes care has improved considerably in the period 1998–2013 in both sexes.
Possibly relevant trend differences between sexes were observed for HbA1c, systolic blood
pressure, BMI and smoking. The predicted mortality risk decreased over time in both sexes.
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Except for BMI in both age groups and systolic blood pressure in patients75 years, no evi-
dent poorer risk factor control in women compared to men was found at the end of the study
period.
Introduction
It is reported in the literature that the risk of cardiovascular mortality is increased about two-
fold in men and threefold in women with type 2 diabetes (T2D) compared with men and
women without T2D [1,2]. A poorer control of cardiovascular risk factors in women with T2D
compared to men is considered as a possible explanation for this difference [1]. Some studies
indicate that target levels for clinical parameters are less frequently achieved in women [3–7].
In an Italian study for example, the target value for HbA1c (<53 mmol/mol) was achieved in
34% of women compared to 40% of men [3]. The percentage of women who achieved the target
value for systolic blood pressure appears to be 2 to 4% lower than in men [3–5]. Some studies
indicate sex disparities in treatment intensity as the explaining factor for this difference in risk
factor control whereas others describe that this difference could be explained by psychosocial
mechanisms, like patient compliance [5,6].
Taken together, it could be that there is a difference in quality of care for men and women
with T2D. One way to assess quality of diabetes care is by using quality indicators. Quality of
care is hereby captured in process and outcome measures which are based on national and/or
international guidelines. Process measures indicate the number of patients in which a physical
examination or laboratory test is performed and an outcome measure reflects the actual results
of the assessments and interventions. Measuring the same process and outcome measures over
time makes it possible to measure changes in diabetes care and to investigate if the changes dif-
fer between sexes over time. The existence of possible differences may indicate that there
should be more emphasis on sex-specific diabetes care.
A previous study from our study group showed that quality of diabetes care has consider-
ably improved in the period 1998–2008 [8]. Possible sex disparities and whether these dispari-
ties have changed over time have not been investigated in our previous study. Investigating sex
differences in this study makes it possible to measure trends in possible sex differences, instead
of measuring cross-sectional differences only which has been done in most of the previous
studies. Therefore, the aim of the current study was to investigate whether trends in quality of
diabetes care differed between sexes in the Netherlands from 1998 until 2013 in patients<75
years and in the subgroup of patients>75 years of age.
Materials and Methods
This study uses, to some extent, the methodology as published before [8].
Study population
The study population consisted of patients who are included in the Zwolle Outpatient Diabetes
project Integrating Available Care (ZODIAC) project. This project started in 1998 as a study to
investigate the effects of shared care for patients with T2D who are treated in primary care [9].
Due to positive results, this shared care initiative became the standard care for the Zwolle
region in 2002. In 2006, 2009 and 2012, it expanded to other regions which are connected to
our diabetes centre for benchmark and research purposes.
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Only T2D patients treated in primary care are included in the ZODIAC project. Patients
with a very short life expectancy or insufficient cognitive capabilities are excluded from partici-
pation. At the start in 1998, 53 general practitioners (GPs) participated in this project, and this
number increased to 731 GPs in 2013. All patients who were participating for at least one year
in the ZODIAC project between 1998 and 2013 were included in the current study.
Data collection and outcome measures
Quality measures, based on the guidelines of the Dutch College of General Practitioners and
the Dutch Diabetes Federation, are collected in the general practitioners’ (GP) patient informa-
tion systems, mostly by practice nurses. As part of the shared care initiative, clinical data are
uploaded and sent to our Diabetes Centre for benchmarking and research purposes annually.
All general practices use the same system to upload their data about the patients with T2D. In
the first years, practice nurses had to fill in the information system manually. Nowadays, most
of the information is automatically extracted from the patient information systems of the gen-
eral practices.
In the current study, process and outcome measures were assessed. All process and outcome
measures are depicted in Table 1.
To estimate the 10-year mortality risk based on a part of the outcome measures, the Globor-
isk risk equation was used [10]. This risk prediction equation includes sex, age, smoking, blood
pressure, total cholesterol and diabetes to predict 10-year cardiovascular mortality risk. Mortal-
ity risk was assessed in patients<75 years of age without a history of cardiovascular disease
(CVD). Not having CVD was defined as not using thrombocyte aggregation inhibitors and not
having a registration for a history of angina pectoris, myocardial infarction, percutaneous
transluminal coronary angioplasty, coronary artery bypass grafting, stroke or transient ische-
mic attack in the GPs’ patient information system. A country-specific risk chart for the Nether-
lands was not available so therefore the risk chart of Denmark, a country with a more or less
comparable population composition and comparable quality of diabetes care compared to the
Netherlands, was used [11]. Low risk was defined as a cardiovascular mortality risk below 10%,
medium risk as a risk between 10 to 20% and a high risk as a risk above 20%.
Statistical analyses
Main analyses were performed in men and women<75 years of age. Subgroup analyses were
performed in men and women75 years of age. Patients were divided in these two age groups
to create a comparable mean age for men and women for the visual analyses and because of the
limited evidence for the treatment of T2D and cardiovascular risk management in patients
aged older than 75 years. Data were expressed as mean or median with 95% confidence interval
(CI) for normally distributed and non-normally distributed data, respectively. Nominal vari-
ables are represented as the proportion of patients with 95% CI. The descriptive statistics for
each year were cross-sectional and included data of all visits. Cross-sectional outcomes tend to
overestimate time trends compared to longitudinal analyses [12]. Therefore, the existence of a
linear time trend from 1998 to 2013 was tested using a generalized linear mixed model (PROC
GLIMMIX) with a normal distribution for continuous variables and a binomial distribution
using the logit link function for binary variables, both adjusted for age and sex. Model fit of the
(generalized) linear mixed models was measured using a correlation method which was pro-
posed by Zheng et al. [13]. All trends were visually inspected and the results of quadratic trend
analysis were only included when such a trend was likely based on the plot and when there was
a substantial increase in model fit. Time, age and sex (if applicable) were modelled as fixed
effects in the analyses. Since the estimated linear time trends are based on individual changes
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over time, data of at least two visits were necessary. Trend and absolute differences between
both sexes were investigated visually and by adding sex as an interaction term and confounder
to the models. Trends were also investigated in stratified analyses according to sex. Trend and
absolute differences between sexes were marked as possible relevant when clear differences
were observed visually. All descriptive analyses were performed with SPSS V.20 software and
all mixed model analyses with SAS V.9.2 software.
Ethical approval
The ZODIAC study and the informed consent procedure were approved by the local medical
ethics committee of the Isala, Zwolle, the Netherlands. In the first years of ZODIAC, verbal
informed consent was obtained from all patients and the consent was documented in the
patient’s records. According to Dutch law, written informed consent was not necessary for this
type of study in 1998. Nowadays, written informed consent is obtained. All data were analysed
anonymously.
Table 1. Process and outcomemeasurements.
Parameter Process measure Outcome measure
HbA1c Percentage of patients measured Mean HbA1c (mmol/mol)
Percentage HbA1c >53 mmol/mol
Diabetes treatment Not applicable Percentage diet only
Percentage oral medication only
Percentage insulin with or without oral medication
Systolic blood
pressure
Percentage of patients measured Mean SBP (mmHg)
Percentage SBP 140 mmHg
Hypertension
treatment
Not applicable Percentage patients using
antihypertensive drugs
Cholesterol-HDL
ratio
Percentage of patients measured Mean cholesterol-HDL ratio
Percentage cholesterol-HDL ratio 4
Lipid lowering
treatment
Not applicable Percentage of patients using lipid lowering drugs
Renal function Percentage of patients with ACR measurements Percentage microalbuminuria: Women: ACR 3.5–35 mg/mmol; Men: ACR
2.5–25 mg/mmol
Percentage macroalbuminuria: Women: ACR >35 mg/mmol; Men: ACR
>25 mg/mmol
Foot examination Percentage of patient examined. (Tested 5.07 Semmes-
Weinstein monoﬁlaments).
Percentage of patients with diminished sensibility. (Deﬁned as two or
more errors in a test of three per foot).
Eye examination Percentage of patients with retinascreening (investigated
with a retinal camera).
Percentage of patients with DRP.
BMI Percentage of patients measured Mean BMI (kg/m2)
Percentage BMI 25 kg/m2
Percentage BMI 25–30 kg/m2
Percentage BMI 30 kg/m2
Smoking Percentage of patients asked Percentage of smokers
Abbreviations: SBP, systolic blood pressure; HDL, high-density lipoprotein; ACR, albumin-creatinine ratio; DRP, diabetic retinopathy; BMI, body mass
index.
doi:10.1371/journal.pone.0145907.t001
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Results
The number of patients with T2D<75 years increased from 1791 in 1998 to 42,641 in 2013.
The number of patients75 years increased from 853 to 19,589 in the same period. The pro-
portion of men increased over time to 45.8% in patients<75 years in 2013. Median diabetes
duration increased from 4.5 to 6.0 years in patients<75 years. Mean age slightly decreased in
women and increased in men during the study period (women<75: 63.3 to 62.4 years, men
<75: 61.0 to 62.0 years). The cross-sectional results for all process and outcome measures for
patients<75 years are presented in Table 2. Tables stratified for sex are presented in S1 and S2
Tables. The process measures for men and women<75 years are presented in Fig 1 and the
outcome measures for men and women<75 years are presented in Figs 2 and 3. The outcome
measures for men and women>75 years of age are presented in S1 and S2 Figs.
Process measures
A positive trend for men and women<75 years of age was observed for all process measures
with a temporary decrease in 2003 and 2006 for most variables (Fig 1 and Table 2). The process
measures for foot end eye examination showed another trend with a decrease in the period
from 2002 to 2007 and an increase afterwards (Fig 1 and Table 2). Significant trend differences
between sexes were observed for the process measures of renal function and eye examination.
Significant absolute differences between sexes were observed for the process measures of renal
function, eye examination and BMI (Table 2).
Outcome measures for patients up to 75 years of age
In 1998, 50.9% of the men and 59.5% of the women had an HbA1c>53 mmol/mol. This
decreased to 24,9% in women and 26,3% in men in 2008 and increased afterwards to almost
29% in 2013 in both sexes (p for quadratic trend in both sexes<0.001). A small difference in
trend between sexes was observed due to the difference in the first years (p for interaction:
<0.001). In all years, the use of oral medication was on average 3% higher in men (p for sex
<0.001). In the first years, there were more women on insulin compared to men (p for
sex< 0.001), whereas in the last years no sex differences was observed (p for interaction
<0.001). The number of patients with a systolic blood pressure (SBP)>140 mmHg decreased
from 70.1% to 42.0% in men, and from 80.2% to 40.3% in women (p for trend in both sexes
<0.001), whereby a small trend difference between sexes was observed due to the difference in
the first years (p for interaction<0.001). The use of antihypertensive drugs increased over the
years in both sexes in the first half of the study period and decreased slightly afterwards (p for
quadratic trend in both sexes<0.001). This increase was slightly higher in men compared to
women (p for interaction<0.001) but still these medications were more frequently used in
women than men (p for sex<0.001). The percentage of patients with a cholesterol-HDL ratio
4 decreased from 76.2% to 39.4% in men and from 73.8% to 29.9% in women in the period
from 1998 till 2006 and decreased slightly afterwards in both sexes (p for quadratic trend in
both sexes<0.001). A small trend difference between sexes was observed (p for interaction:
<0.001) and the target value was in all years more often achieved in women (p for sex<0.001).
The use of lipid lowering drugs increased over time and they were more often used by men (p
for sex<0.001).
Microalbuminuria was more prevalent in men compared to women (p for sex<0.001).
Both micro- and macroalbuminuria decreased over the years in both sexes (p for trend in both
sexes<0.001). The prevalence of macroalbuminuria decreased from 10.2% to 1.6% in men and
from 7.0% to 0.7% in women (p for interaction = 0.009). Approximately 20% in both sexes had
diminished foot sensibility in 1998, which decreased slightly over time to 10.6% in men and
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Fig 1. Processmeasures in patients <75 years stratified according to sex.Men: gray line, Women: black striped line.
doi:10.1371/journal.pone.0145907.g001
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Fig 2. Outcomemeasures for HbA1c, diabetes treatment, systolic blood pressure, hypertension
treatment, cholesterol-HDL ratio, lipid lowering treatment, renal function and foot and eye
examination in patients <75 years stratified according to sex.Men: gray line, Women: black striped line.
doi:10.1371/journal.pone.0145907.g002
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8.3% in women in 2010. In the last years it increased to 15.3% in men and 12.8% in women (p
for quadratic trend in both sexes<0.001). Diabetic retinopathy decreased from approximately
13% in 1998 to 6% in 2013 in both sexes (p for trend in both sexes<0.001).
The number of men who had a BMI below 25 kg/m2 decreased slightly over time, whereas
for women it remained stable (p for interaction<0.001). In the group of patients with a BMI
>25 kg/m2, men were more frequently overweight and women were more frequently obese.
Obesity increased from 49.6% to 51.9% in women and from 31.0 to 40.3% in men (p for inter-
action<0.031). The percentage of smokers decreased from 34.2% to 21.8% in men and from
21.7% to 17.5% in women (p for trend in both sexes<0.001). A trend difference in favor of
men was observed (p for interaction<0.001). In the most recent years the prevalence of smok-
ers was 4% higher among men compared to women (p for sex<0.001).
Outcome measures for patients 75 years and over
In the age category patients of 75 years and over, similar trends were found for HbA1c, BMI,
insulin use and for the use of antihypertensive and lipid lowering drugs (S1 and S2 Figs). The
target value for systolic blood pressure was more frequently achieved in men compared to
women. The sex difference in the cholesterol-HDL ratio was smaller in patients75 years of
age compared to the younger patients. The prevalence of micro- and macroalbuminuria was
higher in both sexes. The prevalence of diminished sensibility was higher in men compared to
women (p for sex<0.001). The prevalence of DRP was higher in women compared to men (p
for sex<0.001). In women, a small increase in smoking prevalence was observed during the
study period (p for interaction<0.001).
Fig 3. Outcomemeasures for BMI and smoking in patients <75 years stratified according to sex.Men: gray line, Women: black striped line.
doi:10.1371/journal.pone.0145907.g003
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Post-hoc analyses for the period 2006–2013
In the period 2006–2013 for almost all process and outcome measures the same trends were
observed, except for the trends for the outcome measures for HbA1c, renal function, foot
examination and eye examination (S3 Table). In this period, the number of men and women
with an HbA1c>53 mmol/mol slightly increased. The prevalence of microalbuminuria
remained stable in both sexes and the prevalence of diabetic retinopathy and diminished sensi-
bility of the feet increased slightly in both sexes. Significant trend differences between sexes for
the outcome measures were only observed for the use of insulin and antihypertensive drugs
and for the prevalence of smoking.
Risk engine
The estimated 10-year risk of CVD mortality for men and women<75 years of age without a
history of CVD diseases is depicted in Fig 4. The number of patients with a low risk for CVD
mortality (i.e.<10% 10-years mortality prediction) increased from 64.2% in 1998 to 79.5% in
2013 in men and from 56.1% to 80.5% in women in the same period.
Discussion
In this study, gender differences in the quality of diabetes care were assessed using process and
outcome measures. Possibly relevant trend differences in the improvement of the quality of
care between sexes were only observed for the outcome measures of HbA1c, systolic blood
pressure, BMI and smoking and these trends converged between sexes over time. No relevant
trend differences between sexes were observed for the process measures. All process and out-
come parameters improved in the period from 1998 to 2013 in both sexes except for the pro-
portion of patients with normal BMI. At the end of the study period, possibly relevant absolute
sex differences were observed for cholesterol-HDL ratio, albuminuria, BMI and smoking. Fur-
thermore, possibly relevant absolute differences in medication use were observed for the use of
insulin in the first half of the study period and for antihypertensive drugs and lipid lowering
drugs in the whole study period.
In the most recent years almost all process and outcome measures reached a plateau phase,
which could imply that for those indicators the (near) maximal attainable goal in relation to
effort is already achieved. For the outcome measures of HbA1c, foot examination and eye
examination significant deteriorations were observed as shown in the analyses for the period
2006 to 2013. However, these deteriorations are probably not relevant, as the lines in the graphs
are almost horizontal.
Many studies have mentioned that cardiovascular risk factors are poorer controlled in
women compared to men [3,5,6,14]. In our study, this finding could only be confirmed for
BMI in both age groups and for SBP in patients75 years of age. Women had even better cho-
lesterol-HDL ratios, less frequently albuminuria, less frequently diminished sensibility and also
smoked less compared to men. The difference between the findings of our study and others
could possibly be explained by the well-organized care for diabetes patients in the Netherlands
[8]. In this protocol-based care, it is unlikely that women are treated less aggressively. This
explanation is widely discussed in a previous study from the same cohort [8]. The explanation
could possibly also be found in the interpretation of the results. In previous studies, conclusions
concerning sex differences are sometimes based on very small absolute differences and one can
doubt about their clinical relevance.
Based on the results of the risk equation, the risk of cardiovascular mortality decreased over
time in our study population in both men and women. In 1998, there were more women than
men with an intermediate or high mortality risk but the risk at the end of the study period was
Sex Differences in Diabetes Care
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Fig 4. 10-years risk of cardiovascular mortality for men and women <75 years of age without a history of CVD.
doi:10.1371/journal.pone.0145907.g004
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comparable between sexes. However, this could mean that the risk is relatively higher for
women, given the fact that women have a lower mortality risk compared to men in the general
population. It remains to be determined in future studies whether the comparable cardiovascular
risk will also translate into a comparable mortality risk in our population. In the literature, a
higher relative risk for cardiovascular mortality in women with T2D is described [1,2]. Our
results indicate that this higher risk in women with T2D is probably not explained by differences
in risk factor control between men and women with T2D. However, it might be due to a greater
difference in cardiovascular risk factor control between women with and without T2D compared
to men with and without T2D [1,15]. Differences in physical activity between men and women
could also play an important role [14,16]. Furthermore, women with T2D and coronary athero-
sclerosis have less obstructive disease compared to men, with higher rates of microvascular coro-
nary dysfunction that may be more difficult to diagnose and treat [17]. Also, a higher prevalence
heart failure with preserved ejection fraction (HFpEF) in described in women compared to men
with T2D [18]. The higher inflammatory state and unfavorable alterations of the coagulation sys-
tem in postmenopausal women, may further enhance their higher CVD risk [19]. It remains to
be determined whether focussing on these aspects may improve long-term outcomes in women.
Some limitations of this study need to be mentioned. First, the clinical data and the data on
medication use in our study are collected by practice nurses and GPs and sent to our Diabetes
Centre as part of the yearly benchmark of this project. The quality and reliability of the data are
therefore dependent on the accuracy of the data providers. For example, all process measures
showed more or less the same trend with a temporary decrease in 2003 and 2006 which could
be explained by the introduction of new regions in those specific years. Lack of experience with
using the core data set and properly registering of this data in the first year, and as a conse-
quence underreporting on specific data entry positions, may explain the initial lack of data. Sec-
ond, different laboratories were participating in this project and different methods were used for
assessing the blood samples. However, due to the high number of patients in the last years of the
project, it is not likely that differences in laboratory methods have influenced the trend results.
Third, especially for some process measures, a low model fit was found due to a high variation
between years in achieving the process measures. The trend of these process measures should
therefore be interpreted with caution. Fourth, whether a difference was described as relevant
was based on the interpretation of the authors. Fifth, only the presence of gender differences in
process and outcome measures was assessed. Possible explanations for these differences were
not investigated. At last, despite of the use of two age groups, still a small difference in mean age
between men and women was observed which could theoretically have influenced the results.
In conclusion, quality of care for patients with T2D within this study, has improved consid-
erably in the period 1998–2013 in both sexes. Possibly relevant trend differences in the
improvement of the quality of care between sexes were only observed for HbA1c and systolic
blood pressure BMI and smoking and all these trends converged over time. The predicted mor-
tality risk improved in men and women and also converged between both sexes over time.
Except for BMI in both age groups and systolic blood pressure in patients75 years of age, no
evident poorer risk factor control in women compared to men was found.
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S1 Fig. Outcome measures for HbA1c, diabetes treatment, systolic blood pressure, hyper-
tension treatment, cholesterol-HDL ratio, lipid lowering treatment, renal function and
foot and eye examination in patients>75 years stratified according to sex.Men: gray line,
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